StockData

ImageneBio vs Palisade Bio

IMA and PALI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IMA and PALI compare

Palisade Bio is the larger company, worth 4.9 times as much as ImageneBio ($179M against $36.3M).

Palisade Bio scores higher on the StockData Score (7 against 6 for ImageneBio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIMAPALI
Size and price
Market cap$36.3M$179M
Share price$3.20$1.03
Change, 1 year−61.6%−44.9%
Change, 5 years−98.3%−99.9%
Beta (5Y)0.831.13
Employees15100K
StockData Score
Total score67 (better)
Valuation score11
Growth score00
Performance score01 (better)
Health score55
Dividend score00
Valuation
P/S–359×
P/B0.3× (better)1.5×
Growth
Revenue growth, 5Y average−38.6%–
Profitability
Operating margin–−7070%
Net margin–−6388%
Return on equity–−51.4%
Financial health
Debt / equity0.000.00
Interest coverage–−4418.6×
Current ratio21.4724.26 (better)
Altman Z-score−0.3419.58 (better)
Piotroski F-score5 (better)4
Dividends and buybacks
Buyback yield–−73.2%
Shareholder yield0.00% (better)−73.2%
Ownership
Held by institutions54.9%99.5%
Held by insiders52.9%4.7%
Insider net buying, 12 months$78.5K (better)−$124K
Short interest, % of float0.86%17.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.